Multicenter randomized double-blind double-dummy active-comparator event-driven superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with a recent Embolic Stroke of Undetermined Source (ESUS) comparing rivaroxaban 15 mg once daily with aspirin 100 mg (NAVIGATE ESUS)

Brief Description Of Study

This randomized trial will evaluate the use of rivaroxaban vs. aspirin in reducing the risk of recurrent stroke on patients with a recent embolic stroke of undetermined source. Subjects must be 18 or over and have had an ESUS within 6 months of study enrollment.

Clinical Study Identifier: 821236

Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: Multicenter randomized double-blind double-dummy active-comparator event-driven superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with a recent Embolic Stroke of Undetermined Source (ESUS) comparing rivaroxaban 15 mg once daily with aspirin 100 mg (NAVIGATE ESUS)
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.